Michael A. Vogelbaum

Michael A. Vogelbaum's AcademicInfluence.com Rankings

Philosophy

#8466

World Rank

#11855

Historical Rank

Logic

#5496

World Rank

#6901

Historical Rank

philosophy Degrees

Michael A. Vogelbaum

Biology

#11459

World Rank

#14857

Historical Rank

Neuroscience

#1860

World Rank

#1916

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Michael A. Vogelbaum's Degrees

Doctorate Medicine University of Pennsylvania
PhD Neuroscience University of Pennsylvania

Why Is Michael A. Vogelbaum Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael A. Vogelbaum's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. (2010) (2448)
A randomized trial of bevacizumab for newly diagnosed glioblastoma. (2014) (2145)
Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline (2012) (557)
Response assessment criteria for brain metastases: proposal from the RANO group. (2015) (553)
Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. (2016) (550)
Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. (2015) (441)
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. (2015) (438)
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. (2010) (403)
Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells (2002) (383)
Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. (2014) (304)
Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. (2011) (303)
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study (2017) (271)
Serum S100β (2003) (238)
End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. (2009) (238)
Response Assessment in Neuro-Oncology Clinical Trials. (2017) (226)
Poor drug distribution as a possible explanation for the results of the PRECISE trial. (2010) (224)
Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. (2006) (217)
Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group (2012) (205)
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme (2010) (194)
Updates in the management of brain metastases. (2016) (194)
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. (2014) (182)
Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. (2015) (175)
Cancer Stem Cell‐Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion (2016) (167)
In Touch with Robotics: Neurosurgery for the Future (2005) (165)
Function of the Blood-Brain Barrier and Restriction of Drug Delivery to Invasive Glioma Cells: Findings in an Orthotopic Rat Xenograft Model of Glioma (2013) (158)
IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. (2002) (156)
Intracranial meningiomas of atypical (WHO grade II) histology (2010) (154)
Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group. (2015) (151)
Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. (2016) (147)
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma (2016) (145)
Glioblastoma Cancer Stem Cells Evade Innate Immune Suppression of Self-Renewal through Reduced TLR4 Expression. (2017) (139)
PET imaging in patients with meningioma—report of the RANO/PET Group (2017) (135)
DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. (2019) (128)
CONVECTION‐ENHANCED DELIVERY OF CINTREDEKIN BESUDOTOX (INTERLEUKIN‐13‐PE38QQR) FOLLOWED BY RADIATION THERAPY WITH AND WITHOUT TEMOZOLOMIDE IN NEWLY DIAGNOSED MALIGNANT GLIOMAS: PHASE 1 STUDY OF FINAL SAFETY RESULTS (2007) (128)
RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). (2013) (124)
Conventional MRI does not reliably distinguish radiation necrosis from tumor recurrence after stereotactic radiosurgery (2012) (122)
A nomogram for individualized estimation of survival among patients with brain metastasis. (2012) (122)
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC (2018) (120)
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria (2014) (120)
Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70. (2005) (118)
Clinical trial end points for high-grade glioma: the evolving landscape. (2011) (117)
Resectable brain metastases. (2006) (117)
Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. (2013) (115)
Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes (2015) (112)
Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. (2018) (112)
Convection-enhanced delivery for the treatment of glioblastoma. (2015) (111)
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. (2013) (109)
Dose-dependent cross-talk between the transforming growth factor-β and interleukin-1 signaling pathways (2007) (107)
Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution. (2009) (103)
Novel drug delivery strategies in neuro-oncology (2009) (103)
Aberrant constitutive activation of nuclear factor κB in glioblastoma multiforme drives invasive phenotype (2007) (102)
Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2. (2005) (101)
Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older (2012) (101)
Results of a Survey of Neurosurgical Practice Patterns Regarding the Prophylactic use of Anti-Epilepsy Drugs in Patients with Brain Tumors (2005) (100)
Results of a phase II trial of the GliaSite radiation therapy system for the treatment of newly diagnosed, resected single brain metastases. (2006) (98)
Salvage stereotactic radiosurgery effectively treats recurrences from whole‐brain radiation therapy (2008) (98)
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. (2021) (97)
QUANTUM DOTS ARE PHAGOCYTIZED BY MACROPHAGES AND COLOCALIZE WITH EXPERIMENTAL GLIOMAS (2007) (96)
Future of convection-enhanced delivery in the treatment of brain tumors. (2010) (94)
Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. (2016) (88)
Treatment of five or more brain metastases with stereotactic radiosurgery. (2009) (87)
High-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539. (2016) (86)
Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. (2018) (86)
An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. (2016) (86)
Association Between Radiation Necrosis and Tumor Biology After Stereotactic Radiosurgery for Brain Metastasis. (2016) (84)
Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. (2011) (84)
Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner (2020) (84)
Imaging and diagnostic advances for intracranial meningiomas. (2019) (83)
RPA classification has prognostic significance for surgically resected single brain metastasis. (2006) (82)
Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications (2019) (81)
The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities. (2016) (80)
The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies (2017) (79)
Developmental Regulation of Apoptosis in Dorsal Root Ganglion Neurons (1998) (75)
Convection enhanced delivery for the treatment of malignant gliomas: symposium review (2005) (75)
Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review (2007) (73)
Multidisciplinary management of colorectal brain metastases (2008) (73)
Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent Glioblastoma Multiforme: Interim results. (2004) (72)
Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm. (2017) (72)
Long-term outcomes of Gamma Knife radiosurgery in patients with vestibular schwannomas. (2011) (71)
IL-8 is a mediator of NF-κB induced invasion by gliomas (2010) (68)
Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions (2012) (67)
Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells (2019) (67)
The Impact of Sequencing PD-1/PD-L1 Inhibitors and Stereotactic Radiosurgery for Patients with Brain Metastasis. (2019) (66)
Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression (2019) (65)
Intracranial navigation by using low-field intraoperative magnetic resonance imaging: preliminary experience. (2002) (64)
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. (2009) (63)
Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study (2010) (63)
Stereotactic radiosurgery for single brainstem metastases: the cleveland clinic experience. (2010) (62)
S100beta as a predictor of brain metastases: brain versus cerebrovascular damage. (2005) (62)
An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825 (2016) (62)
Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme. (2004) (62)
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. (2020) (60)
Posterior Fossa Metastases: Risk of Leptomeningeal Disease When Treated with Stereotactic Radiosurgery Compared to Surgery (2004) (58)
Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: Case report and review of the literature (2001) (57)
Risk Factors for Malignant Transformation of Low-Grade Glioma. (2017) (57)
Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. (2010) (57)
PTPmu suppresses glioma cell migration and dispersal. (2009) (55)
Recent Developments and Future Directions in Adult Lower-Grade Gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus. (2019) (55)
Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma (2019) (55)
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. (2021) (55)
Silencing IL-13Rα2 Promotes Glioblastoma Cell Death via Endogenous Signaling (2011) (53)
Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome. (2017) (53)
The role of 5‐aminolevulinic acid in enhancing surgery for high‐grade glioma, its current boundaries, and future perspectives: A systematic review (2016) (52)
Cyclooxygenase-2 (COX-2) expression by immunohistochemistry in glioblastoma multiforme. (2002) (50)
Supratotal resection in glioma: a systematic review (2018) (49)
Impact of the radiosurgery prescription dose on the local control of small (2 cm or smaller) brain metastases. (2017) (48)
Five-year survivors of brain metastases: a single-institution report of 32 patients. (2006) (48)
Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. (2012) (47)
Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies (2017) (47)
Neoplasms of the central nervous system (2015) (47)
The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. (2006) (46)
Evidence-based recommendations on categories for extent of resection in diffuse glioma. (2021) (46)
Stat3 activation is required for the growth of U87 cell-derived tumours in mice. (2009) (45)
The role of 111indium-octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas (2006) (43)
First-in-human evaluation of the Cleveland Multiport Catheter for convection-enhanced delivery of topotecan in recurrent high-grade glioma: results of pilot trial 1. (2019) (43)
Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial. (2016) (42)
Use of high-field intraoperative magnetic resonance imaging to enhance the extent of resection of enhancing and nonenhancing gliomas. (2014) (42)
Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article. (2011) (42)
Barriers to Accrual and Enrollment in Brain Tumor Trials. (2019) (41)
Management of brain metastases in breast cancer: a review of current practices and emerging treatments (2020) (41)
Is there a shortage of neurosurgeons in the United States? (2013) (41)
Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases. (2020) (40)
Convection-enhanced drug delivery for gliomas (2015) (38)
Imaging characteristics of zinc sulfide shell, cadmium telluride core quantum dots. (2008) (38)
Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. (2018) (37)
p300- and Myc-mediated regulation of glioblastoma multiforme cell differentiation (2010) (37)
EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS: NOVEL THERAPY FOR THE TREATMENT OF HIGH-GRADE GLIOMAS (2004) (37)
Role of Gamma Knife surgery in patients with 5 or more brain metastases. (2012) (37)
Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria. (2017) (37)
The importance of the conformality, heterogeneity, and gradient indices in evaluating Gamma Knife radiosurgery treatment plans for intracranial meningiomas. (2012) (37)
Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis. (2018) (36)
Brain metastases from esophageal cancer: a phenomenon of adjuvant therapy? (2006) (35)
Intraoperative radiotherapy to treat newly diagnosed solitary brain metastasis: initial experience and long-term outcomes. (2015) (35)
Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas (2011) (35)
Use of the Radiation Therapy Oncology Group recursive partitioning analysis classification system and predictors of survival in 19 women with brain metastases from ovarian carcinoma (2005) (34)
Malignant Transformation of Molecularly Classified Adult Low Grade Glioma. (2019) (34)
Posterior Fossa Metastases: Aggressive Treatment Improves Survival (2004) (34)
Cyclooxygenase‐2 in oligodendroglial neoplasms (2003) (32)
Three or More Courses of Stereotactic Radiosurgery for Patients with Multiply Recurrent Brain Metastases (2017) (32)
Stereotactic radiosurgery as single-modality treatment of incidentally identified renal cell carcinoma brain metastases. (2010) (32)
Overexpression of bax in human glioma cell lines. (1999) (32)
Current Management and Treatment Modalities for Intramedullary Spinal Cord Tumors (2015) (32)
Coordination of self-renewal in glioblastoma by integration of adhesion and microRNA signaling. (2016) (32)
Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases. (2019) (32)
CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design. (2020) (31)
Results of a questionnaire regarding practice patterns for the diagnosis and treatment of intracranial radiation necrosis after SRS (2013) (31)
The influence of static stress on the corrosion behavior of 316L stainless steel in Ringer's solution. (1986) (30)
Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). (2013) (30)
Convection-enhanced drug delivery for glioblastoma: a review (2021) (29)
Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group (2018) (28)
SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. (2021) (28)
Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1–3 newly diagnosed brain metastases (2015) (27)
Phase 0 and Window of Opportunity Clinical Trial Design in Neuro-Oncology: A RANO Review. (2020) (27)
Tumor progression in patients receiving adjuvant whole-brain radiotherapy vs localized radiotherapy after surgical resection of brain metastases. (2015) (27)
PL3.3 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion (2019) (26)
Federated learning enables big data for rare cancer boundary detection (2022) (26)
In Touch with Robotics: Neurosurgery for the Future. (2005) (26)
Stereotactic radiosurgical treatment of brain metastases in older patients (2008) (25)
Editorial. COVID-19 and neurosurgical practice: an interim report (2020) (24)
A cure is possible: a study of 10-year survivors of brain metastases (2016) (24)
Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery. (2019) (24)
CODEL (Alliance-N0577; EORTC-26081/22086; NRG-1071; NCIC-CEC-2): Phase III Randomized Study of RT vs. RT+TMZ vs. TMZ for Newly Diagnosed 1p/19q-Codeleted Anaplastic Oligodendroglial Tumors. Analysis of Patients Treated on the Original Protocol Design (PL02.005) (2016) (23)
Radiosurgery for Pediatric Brain Tumors (2016) (23)
Relationship between HER2 status and prognosis in women with brain metastases from breast cancer. (2012) (23)
Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131 (2015) (23)
Gender, race, and survival: a study in non-small-cell lung cancer brain metastases patients utilizing the radiation therapy oncology group recursive partitioning analysis classification. (2009) (23)
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. (2020) (22)
Intracranial collision tumor mimicking an octreotide-SPECT positive and FDG-PET negative meningioma (2005) (22)
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations (2021) (21)
Does extent of resection of a glioblastoma matter? (2012) (21)
GBM Derived Gangliosides Induce T Cell Apoptosis through Activation of the Caspase Cascade Involving Both the Extrinsic and the Intrinsic Pathway (2015) (21)
Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases. (2012) (21)
Towards a standard pathological and molecular characterization of recurrent glioma in adults: a RANO effort. (2019) (20)
Convection-enhanced delivery of therapeutic agents into the brain. (2012) (20)
ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM) (2019) (20)
Quality of Life following Stereotactic Radiosurgery for Single and Multiple Brain Metastases (2017) (20)
Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines* (2019) (20)
Radiation-induced apoptosis in dorsal root ganglion neurons (1997) (20)
Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis. (2019) (20)
The impact of tumor biology on survival and response to radiation therapy among patients with non-small cell lung cancer brain metastases. (2017) (20)
Combined use of minimal access craniotomy, intraoperative magnetic resonance imaging, and awake functional mapping for the resection of gliomas in 61 patients. (2019) (19)
Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. (2009) (19)
The Meningioma Enhancer Landscape Delineates Novel Subgroups and Drives Druggable Dependencies. (2020) (19)
Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma (2019) (19)
Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion. (2019) (19)
Response Assessment in Neuro-Oncology (RANO): more than imaging criteria for malignant glioma. (2015) (19)
Current concepts and newer developments in the treatment of malignant gliomas. (2009) (18)
GNOSIS: Guidelines for Neuro-Oncology: Standards for Investigational Studies — reporting of surgically based therapeutic clinical trials (2007) (18)
Opportunities for clinical research in meningioma (2010) (18)
Stereotactic radiosurgical treatment of parenchymal brain metastases from prostate adenocarcinoma. (2008) (18)
Management of Uncomplicated Skull Fractures in Children:Is Hospital Admission Necessary? (1998) (17)
LTBK-04. PHASE 2 MULTICENTER STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 (TASADENOTUREV) IN COMBINATION WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192) (2020) (17)
Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer (2014) (17)
Treatment of Large Brain Metastases With Stereotactic Radiosurgery (2016) (17)
Phase I Trial of Radiosurgery Dose Escalation Plus Bevacizumab in Patients With Recurrent/Progressive Glioblastoma (2018) (17)
ATIM-24. INTERIM RESULTS OF A PHASE II MULTICENTER STUDY OF THE CONDITIONALLY REPLICATIVE ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB (KEYTRUDA) FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192) (2018) (17)
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma (2021) (17)
Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial (2012) (17)
Phase II trial of erlotinib with temozolomide and concurrent radiation therapy in patients with newly-diagnosed glioblastoma multiforme (2005) (17)
ATCT-16CODEL (ALLIANCE-N0577; EORTC-26081/2208; NRG-1071; NCIC-CEC-2): PHASE III RANDOMIZED STUDY OF RT VS. RT + TMZ VS. TMZ FOR NEWLY DIAGNOSED 1p/19q-CODELETED ANAPLASTIC GLIOMA. ANALYSIS OF PATIENTS TREATED ON THE ORIGINAL PROTOCOL DESIGN. (2015) (16)
Aberrant Stat 3 Signaling by Interleukin-4 in Malignant Glioma Cells : Involvement of IL-13 R a 2 (2005) (16)
LTBK-08. TOCA 511 & TOCA FC VERSUS STANDARD OF CARE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (2019) (16)
Stereotactic radiosurgical treatment of brain metastases to the choroid plexus. (2011) (16)
Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines. (2019) (16)
Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside. (1998) (16)
Mutant circadian period as a marker of suprachiasmatic nucleus function. (1993) (15)
Modern treatment of cerebral metastases: Integrated Medical LearningSM at CNS 2007 (2009) (15)
Convection-Enhanced Delivery of a First-in-Class Anti-β1 Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging (2020) (15)
Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome (2020) (15)
The Cerefy Atlas of Cerebral Vasculature. (2010) (14)
Use of therapeutic drug monitoring to treat Elizabethkingia meningoseptica meningitis and bacteraemia in an adult. (2012) (14)
Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group (2022) (14)
Gamma knife stereotactic radiosurgery for the management of incidentally-identified brain metastasis from non-small cell lung cancer (2011) (13)
Using higher isodose lines for gamma knife treatment of 1 to 3 brain metastases is safe and effective. (2014) (13)
First follow‐up radiographic response is one of the predictors of local tumor progression and radiation necrosis after stereotactic radiosurgery for brain metastases (2017) (13)
The Prognostic Role of Tumor Volume in the Outcome of Patients with Single Brain Metastasis After Stereotactic Radiosurgery. (2017) (12)
IL-13 R 2 , a Decoy Receptor for IL-13 Acts As an Inhibitor of IL-4-dependent Signal Transduction in Glioblastoma Cells 1 (2002) (12)
Prospective Study of the Short-Term Adverse Effects of Gamma Knife Radiosurgery (2012) (12)
Calcifying pseudoneoplasm of the neuraxis overlying the corpus callosum: a case report and review of the literature. (2013) (12)
ATIM-33. INTERIM RESULTS OF A PHASE II MULTI-CENTER STUDY OF ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192) (2019) (11)
Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases (2021) (11)
Update of stereotactic radiosurgery for brain tumors (2004) (11)
Targeted Therapies for Brain Tumors: Will They Ever Deliver? (2018) (11)
Population description and clinical response assessment for spinal metastases: part 2 of the SPIne response assessment in Neuro-Oncology (SPINO) group report (2018) (11)
Cumulative Intracranial Tumor Volume and Number of Brain Metastasis as Predictors of Developing New Lesions After Stereotactic Radiosurgery for Brain Metastasis. (2017) (11)
Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma (2021) (10)
The benefit of surgical resection in recurrent glioblastoma. (2016) (10)
The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. (2021) (10)
Validation of the Disease‐Specific GPA for Patients With 1 to 3 Synchronous Brain Metastases in Newly Diagnosed NSCLC (2018) (9)
Factors Determining the Restoration of Circadian Behavior by Hypothalamic Transplants (1993) (9)
Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O6-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma. (2018) (9)
A Prospective Validation Study of the First 3D Digital Exoscope for Visualization of 5-ALA Induced Fluorescence in High Grade Gliomas. (2021) (9)
Much debated controversies of diffuse low-grade gliomas (2015) (9)
Management of brain metastases (2009) (8)
Towards a genomic definition of completeness of resection? (2014) (8)
AT-02INTRATUMORAL DELIVERY OF THE RETROVIRAL REPLICATING VECTOR (RRV) TOCA 511 IN SUBJECTS WITH RECURRENT HIGH GRADE GLIOMA: INTERIM REPORT OF PHASE 1 STUDY (NCT 01156584) (2014) (8)
Management of Brain Metastasis in Patients With Pulmonary Neuroendocrine Carcinomas (2016) (8)
HOUT-15. BRAIN TUMOR PATIENT AND CAREGIVER SURVEY ON CLINICAL TRIALS: IDENTIFYING ATTITUDES AND BARRIERS TO PATIENT PARTICIPATION (2017) (8)
S100β as a predictor of brain metastases (2005) (7)
Phase II trial of dovitinib in recurrent glioblastoma. (2015) (7)
Therapeutic Delivery to Central Nervous System. (2021) (7)
Impact of preexisting tumor necrosis on the efficacy of stereotactic radiosurgery in the treatment of brain metastases in women with breast cancer (2012) (7)
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial (2022) (7)
Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies (2022) (7)
Low-Risk Meningioma: Initial Outcomes from NRG Oncology/RTOG 0539. (2022) (7)
Long-term trends in glioblastoma survival: implications for historical control groups in clinical trials. (2019) (7)
Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis (2020) (7)
Salvage Stereotactic Radiosurgery Effectively Treats Recurrences From Whole Brain Radiation Therapy (2005) (7)
Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era. (2019) (7)
Deep neural network to locate and segment brain tumors outperformed the expert technicians who created the training data (2020) (7)
Gamma Knife radiosurgery for intracranial hemangioblastoma (2016) (7)
RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas: Relationship between 1p/19q status and progression-free survival. (2005) (7)
Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post-hoc analysis of the EORTC randomized phase 3 CATNON trial. (2022) (7)
Thin layer chromatography-based assay of O6-methylguanine-DNA methyltransferase activity in tissue. (2010) (6)
Quality of Life following Stereotactic Radiosurgery for Single and Multiple Brain Metastases. (2016) (6)
PHASE II TRIAL OF OBSERVATION FOR LOW-RISK MENINGIOMAS AND OF RADIOTHERAPY FOR INTERMEDIATE- AND HIGH-RISK MENINGIOMAS (2014) (6)
Liquid biopsy in gliomas: a RANO review and proposals for clinical applications. (2022) (6)
MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control. (2020) (5)
RANO Criteria: Application to Response Assessment in Clinical Trials (2016) (5)
Optical detection of brain tumors using quantum dots (2005) (5)
Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO/SNO Joint Endorsement Summary of College of Neurologic Surgeons Guidelines. (2019) (5)
ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETION (2019) (5)
Prospective study of the short-term adverse effects of gamma knife radiosurgery. (2007) (5)
Erratum. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. (2018) (5)
Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases (2021) (5)
CLIN-ONGOING CLINICAL TRIALS (2012) (5)
Stereotactic Radiosurgery (SRS) with Immune Checkpoint Inhibitor Therapy (ICI) for Patients with Brain Metastasis (BM): The Impact of Timing and Sequencing (2018) (4)
Response Assessment in Neuro-oncology (RANO): An Update (2018) (4)
Mapping prosody: correlation of functional magnetic resonance imaging with intraoperative electrocorticography recordings in a patient with a right-sided temporooccipital glioma. Case illustration. (2005) (4)
Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside. (1997) (4)
Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline (2022) (4)
Early Results from a Prospective Phase II Dose Escalation Study for Neoadjuvant Radiosurgery for Brain Metastases (2019) (4)
Use of Image Fluorescence in the Resection of Gliomas (2014) (4)
The effect of Gamma Knife radiosurgery on large posterior fossa metastases and the associated mass effect from peritumoral edema. (2020) (4)
Interim results of a Phase II study of resection and GliaSite brachytherapy for a single brain metastasis (2004) (4)
IT-05ADMINISTRATION OF TOCA 511 TO SUBJECTS WITH RECURRENT HGG UNDERGOING REPEAT RESECTION. (2014) (4)
Prospective Phase I Dose Escalation Study for Neoadjuvant Radiosurgery for Large Brain Metastases (2019) (4)
NEURO/MEDICAL ONCOLOGY (2013) (4)
Interrogating the interactions between myeloid derived suppressor cells and cancer stem cells in glioblastoma (2013) (3)
MDNA55: A locally administered IL4 guided toxin as a targeted treatment for recurrent glioblastoma. (2019) (3)
Leveraging the Neurosurgical Operating Room for Therapeutic Development in NeuroOncology. (2022) (3)
331 Association Between Radiation Necrosis and Tumor Biology Following Stereotactic Radiosurgery for Brain Metastasis. (2016) (3)
An Independently Validated Nomogram for Individualized Estimation of Survival Among Patients With Newly Diagnosed Glioblastoma: NRG Oncology/RTOG 0525 and 0825 (2016) (3)
SURG-22. SUPRATOTAL RESECTION IN GLIOMA: A SYSTEMATIC REVIEW (2018) (3)
Quality of life after gamma knife radiosurgery for benign lesions: a prospective study. (2012) (3)
Encouraging survival with Toca 511 and Toca FC compared to external lomustine control. (2016) (3)
Ascending dose trials of the safety and tolerability of Toca 511, a retroviral replicating vector encoding cytosine deaminase, in patients with recurrent high-grade glioma. (2012) (3)
The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIs (2021) (3)
IMMUNOTHERAPY/BIOLOGICAL THERAPIES (2013) (3)
ACTR-04. RESULTS OF THE INTERIM ANALYSIS OF THE EORTC RANDOMIZED PHASE III CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CO-DELETION, AN INTERGROUP TRIAL (2016) (3)
CTNI-29. CODEL: PHASE III TRIAL OF RT ALONE, RT PLUS TMZ, OR TMZ ALONE FOR NEWLY-DIAGNOSED, 1p/19q CODELETED ANAPLASTIC OLIGODENDROGLIOMA. ANALYSIS FROM THE INITIAL STUDY DESIGN. (NCCTG N0577, ALLIANCE) (2020) (3)
Role of stereotactic radiosurgery for multiple (>4) brain metastases. (2011) (3)
OS09.6 Long-term follow-up data from 126 patients with recurrent high grade glioma from three Phase 1 trials of Toca 511 and Toca FC: Update and justification for a Phase 2/3 trial (2017) (2)
DDEL-06PRELIMINARY SAFETY OF TOCA 511, A RETROVIRAL REPLICATING VECTOR, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA ACROSS THREE SEPARATE PHASE 1 STUDIES (2015) (2)
THE ROLE OF MYELOID DERIVED SUPPRESSOR CELLS (MDSCS) IN TUMOR-INDUCED IMMUNOSUPPRESSION IN HUMAN AND MURINE GLIOMAS (2014) (2)
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, "windowofopportunity" study. (2022) (2)
Constitutive activation of NF-kB is present in malignant gliomas and may serve as a therapeutic target (2004) (2)
A Cure Is Possible: A Study of 10 Year Survivors of Brain Metastases (2015) (2)
Evolution of the Neurosurgeon's Role in Clinical Trials for Glioblastoma: A Systematic Overview of the Clinicaltrials.Gov Database (2021) (2)
Glioblastoma in the elderly: The Cleveland Clinic experience (1992-2010). (2011) (2)
ATIM-02. SUCCESSFUL CANCER-SELECTIVE GENE DELIVERY FOLLOWING INTRAVENOUS TOCA 511 DELIVERY IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (HGG) (2016) (2)
Evaluation of Prognostic Factors for Early Mortality After Stereotactic Radiosurgery for Brain Metastases: a Single Institutional Retrospective Review (2018) (2)
Barriers to Delivery of Therapeutics to Brain Tumors (2011) (2)
CTNI-57. LOW-RISK MENINGIOMA: OUTCOMES FROM NRG ONCOLOGY/RTOG 0539 (2020) (2)
Aggressive Treatment is Appropriate for Elderly (70 years and older) Patients with Glioblastoma Multiforme: A Retrospective Review of 206 Cases (2008) (2)
Prognostic factors in elderly patients with grade 3 gliomas. (2011) (2)
New Classification Scheme to Predict Survival in Patients with Brain Metastases from Non-small Cell Lung Cancer Treated with Upfront Stereotactic Radiosurgery (2008) (2)
331 Association Between Radiation Necrosis and Tumor Biology Following Stereotactic Radiosurgery for Brain Metastasis. (2016) (2)
TERT promotor status does not add prognostic information in IDH-wildtype glioblastomas fulfilling other diagnostic WHO criteria: A report of the RANO resect group (2022) (2)
O7.01RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR BRAIN METASTASES (2014) (2)
Prognostic Factors for Patients with a Single Brain Metastasis Treated Primarily with Surgical Resection at a Single Institution (2005) (1)
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline (2021) (1)
Molecular determinants of outcomes in meningiomas (2022) (1)
PATH-11. PROGNOSTIC SIGNIFICANCE OF EPIGENETIC SUBTYPES AND CpGs ASSOCIATED WITH PROGRESSION TO G-CIMP LOW IN THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON (2020) (1)
Do gender and race influence survival in patients with non-small cell lung cancer brain metastases? An outcomes study utilizing the RTOG RPA class stratification. (2006) (1)
What drives patient outcomes in brain metastases: Number, volume, or biology? (2017) (1)
Presentation and management of patients with brain metastases of primary melanoma, non-small cell lung cancer, and breast cancer origin. (2021) (1)
Surgical Adjuncts for Glioblastoma. (2021) (1)
RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas: Relationship between 1p/19q status and progression-free survival (2006) (1)
Validation of the ‘Lesion Quotient’ as a Radiographic Tool to Distinguish between Radiation Necrosis and Tumor Progression for Brain Metastases Treated with Stereotactic Radiosurgery (2010) (1)
Clinical Outcomes of Breast Cancer Brain Metastases Treated with Stereotactic Radiation and Capecitabine (2020) (1)
DDEL-07INTRAVENOUS TOCA 511 DELIVERY LEADS TO VIRAL DNA IN RESECTED HGG (2015) (1)
Management of Brain Metastasis on Patients With Neuroendocrine Carcinomas of the Lung (2014) (1)
A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology. (2022) (1)
Durable complete responses observed in IDH1 mutated high grade glioma at first recurrence undergoing treatment with Toca 511 and Toca FC. (2017) (1)
Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets (2021) (1)
IMCT-04TOCA 5: PHASE 2/3 RANDOMIZED, OPEN-LABEL STUDY OF TOCA 511 WITH TOCA FC VERSUS STANDARD OF CARE IN PATIENTS UNDERGOING PLANNED RESECTION FOR RECURRENT HIGH GRADE GLIOMA (NCT02414165). (2015) (1)
BM-20EVALUATION OF RISK FACTORS FOR DEATH WITHIN THREE MONTHS AFTER STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES. (2014) (1)
ATIM-26. IMMUNOLOGIC TRENDS ASSOCIATED WITH PATIENT OUTCOMES IN A PHASE 1 CLINICAL TRIAL OF TOCA 511 AND TOCA FC IN RECURRENT HIGH GRADE GLIOMA (2018) (1)
Table of Contents by Topic. (2012) (1)
SURG-09RESULTS OF A DOSE ESCALATION TRIAL OF TOCA 511 WITH TOCA FC IN RECURRENT HGG UNDERGOING REPEAT RESECTION. (2015) (1)
Ascending dose trials of a retroviral replicating vector (Toca 511) in patients with recurrent high-grade glioma. (2014) (1)
Therapeutic Discovery Silencing IL-13 R a 2 Promotes Glioblastoma Cell Death via Endogenous Signaling (2011) (1)
ATIM-05. COMPLEMENTARY CLINICAL AND ANCILLARY DATA FROM 123 PATIENTS WITH RECURRENT HIGH GRADE GLIOMA FROM THREE PHASE 1 TRIALS OF TOCA 511 AND TOCA FC: UPDATE AND JUSTIFICATION FOR A PHASE 2/3 TRIAL (2016) (1)
Medical and Neuro-Oncology (2010) (1)
ATIM-17. INVESTIGATION OF ANTI-TUMOR CELLULAR IMMUNE RESPONSE ELICITED BY TOCA 511 & TOCA FC THERAPY IN A RECURRENT HGG PHASE 1 TRIAL (2016) (1)
ATIM-21. INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH HIGH GRADE GLIOMA RESULTS IN QUANTIFIABLE EXPRESSION OF CYTOSINE DEAMINASE IN TUMOR TISSUE. (2017) (1)
ATIM-05. INTRATUMORAL DELIVERY OF MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, BY MRI-GUIDED CONVECTIVE DELIVERY FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA (2018) (1)
Changing Trends in Brain Metastasis: A 20-Year Review of Patient Outcomes (2016) (1)
Clinical Outcomes of Breast Cancer Patients with HER2-positive Brain Metastases Treated with Stereotactic Radiation and Trastuzumab Emtansine (2020) (1)
CTIM-13. CLINICAL EFFICACY OF MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, IN RECURRENT GBM DELIVERED BY CONVECTION ENHANCED DELIVERY (CED) (2020) (1)
Medical and Neuro-Oncology (2010) (1)
CTNI-23. IDH1/2wt ANAPLASTIC GLIOMAS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL: OVERALL SURVIVAL RELATED TO TREATMENT, MGMT STATUS AND MOLECULAR FEATURES OF GLIOBLASTOMA (2020) (1)
OMICS AND PROGNSTIC MARKERS (2013) (1)
Patient satisfaction and cost savings analysis of the telemedicine program within a neuro-oncology department (2022) (1)
Primary medical therapy for BRAFV600E-mutant melanoma brain metastases-is this good enough? (2017) (1)
ATIM-30. COMBATING RECURRENT GLIOBLASTOMA WITH MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, THROUGH MRI-GUIDED CONVECTIVE DELIVERY (2019) (1)
Use of Concurrent TKIs With SRS is Associated With an Increased Rate of Radiation Necrosis Among Patients With Renal Cell Carcinoma Brain Metastasis (2017) (1)
61. Ascending Dose Trials of a Retroviral Replicating Vector (Toca 511) in Patients with Recurrent High-Grade Glioma: Clinical Update, Molecular Analyses, and Proposed Mechanism of Action (2016) (1)
Pathological Correlation of Cellular Imaging using Apparent Diffusion Coefficient (ADC) quantification in patients with Brain Metastases following Gamma Knife Radiosurgery. (2019) (1)
A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma (2022) (1)
Management of Brain Metastases in Patients With SCLC: Defining the Role for Stereotactic Radiosurgery (2015) (1)
LMD-05. Phase 1B Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD): Preliminary Results (2021) (1)
Treatment Outcomes for Patients with Low Karnofsky Performance Status at Presentation with Glioblastoma Multiforme at a Tertiary Care Institution (2008) (1)
Personalized therapeutic delivery in the neurosurgical operating room (2018) (1)
TRLS-05. EARLY RESULTS FROM A PROSPECTIVE PHASE I/II DOSE ESCALATION STUDY OF NEOADJUVANT RADIOSURGERY FOR BRAIN METASTASES (2019) (1)
Replicative Instability Drives Cancer Progression (2022) (1)
Prognostic factors in patients with WHO grade 3 gliomas: The Cleveland Clinic experience. (2011) (1)
The NXDC-MEN-301 Study on 5-ALA for Meningiomas Surgery: An Innovative Study Design for the Assessing the Benefit of Intra-Operative Fluorescence Imaging (2022) (1)
Nodular Leptomeningeal Disease After Surgery for a Brain Metastasis - Should We Be Concerned? (2019) (1)
SURG-10. CONVECTION ENHANCED DELIVERY OF TOPOTECAN AND GADOLINIUM FOR RECURRENT GBM VIA THE CLEVELAND MULTIPORT CATHETER: A FIRST IN HUMAN STUDY (2017) (1)
RBTT-11. NRG ONCOLOGY NRG-BN006: A PHASE II/III RANDOMIZED, OPEN-LABEL STUDY OF TOCA 511 AND TOCA FC WITH STANDARD OF CARE COMPARED TO STANDARD OF CARE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2019) (1)
ME-15INTERACTION BETWEEN CANCER STEM CELLS AND MYELOID DERIVED SUPPRESSOR CELLS DRIVES IMMUNOSUPPRESSION AND GLIOBLASTOMA GROWTH. (2014) (1)
Small Molecule Agents (2007) (1)
Results of a Questionnaire for Diagnosis and Treatment of Brain Radiation Necrosis (2012) (0)
Author Correction: Federated learning enables big data for rare cancer boundary detection (2023) (0)
CLIN-NEURO/MEDICAL ONCOLOGY (2012) (0)
Institutional Experience of High-Risk, Low-Grade Glioma in the Temozolomide Era (2016) (0)
366 Cumulative Intracranial Tumor Volume and Number of Brain Metastasis as Predictors of Developing New Lesions after Stereotactic Radiosurgery for Brain Metastasis (2017) (0)
BIOM-02. LEPTOMENINGEAL DISEASE SECONDARY TO MELANOMA: UPDATES ON THE VALIDITY OF THE VERIDEX CELLSEARCH SYSTEM (2021) (0)
CMET-10. RISK OF RADIATION NECROSIS FOLLOWING REPEAT STEREOTACTIC RADIOSURGERY FOR RECURRENT BRAIN METASTASES (2018) (0)
DNA methylation and survival differences associated with the type of IDH mutation in 1p/19q non-codeleted astrocytomas (2020) (0)
TMIC-53. DEVELOPMENT OF A GEO-TAGGED TUMOR SAMPLE REGISTRY; LINKAGE OF TUMOR SAMPLE LOCATION TO IMAGING CHARACTERISTICS (2022) (0)
Patients With Brain Metastases Treated Across Two Decades: Times Change But Does Survival Stay the Same? (2015) (0)
CD70 and ganglioside expression by GBM induce T-cell apoptosis which is protected by desferoxamine (2005) (0)
RADT-02. CLINICAL OUTCOMES OF BREAST BRAIN METASTASES BY SUBTYPE FOLLOWING LINAC BASED STEREOTACTIC RADIATION (2020) (0)
OS8 - 150 Encouraging Survival with Toca 511 and Toca FC Compared to External Lomustine Control (2016) (0)
GENO-30DISTINCT GENE EXPRESSION PROFILE THAT IS NOT A KNOWN SURVIVAL PREDICTOR IN TUMORS FROM LONG-TERM HIGH GRADE GLIOMA SURVIVORS TREATED WITH A RETROVIRAL REPLICATING VECTOR ENCODING YEAST CYTOSINE DEAMINASE (2015) (0)
Prior Radiation in Subjects Who Were Treated With Toca 511 and Toca FC Across 3 Toca 511 Phase 1 Trials (2016) (0)
Impact of Radiosurgery Dose for Brain Metastases Less Than or Equal to 2 cm in Size (2016) (0)
Microsoft Word-31688198-file00 (2012) (0)
RADI-35. AN ANALYSIS OF RESPONSE ENDPOINTS FOR BRAIN METASTASIS PATIENTS TREATED WITH STEREOTACTIC RADIOSURGERY AND PD(L)-1 INHIBITORS (2019) (0)
Multiple Courses of Stereotactic Radiosurgery for Patients With Multiply Recurrent Brain Metastases (2015) (0)
Gamma Knife Radiosurgery for Single Brain Stem Metastases: The Cleveland Clinic Experience (2008) (0)
Clinical Development of an Anti- β1 Integrin Antibody for the Treatment of High-Grade Glioma via Convection Enhanced Delivery (2020) (0)
CMET-09. IMPACT OF STEROIDS ON THE EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER BRAIN METASTASES (2018) (0)
SURG-10TRANSCRANIAL TOCA 511 FOLLOWED BY TOCA FC IN SUBJECTS WITH RECURRENT HIGH GRADE GLIOMA (HGG) (2015) (0)
High-Grade Gliomas: Diagnosis and Treatment, Gene H. Barnett, Springer, 2007, 1597451851, 9781597451857, 508 pages. Leaders in the field provide the latest information on the diagnosis and management of high-grade gliomas in this new groundbreaking text. The entire spectrum of issues (2010) (0)
High Versus Standard Isodose Lines Has Equivalent Efficacy in Gamma-knife Treatment of 1-3 Brain Metastases (2012) (0)
Results of Stereotactic Radiosurgery for Brain Metastases From Breast Cancer (2007) (0)
Clinical Methods of Nervous System Drug Delivery for Tumors (2019) (0)
The Economic Implication of Upfront Whole-Brain Radiation Therapy for Patients With Limited Brain Metastasis (2016) (0)
STEM-10. BIDIRECTIONAL INTERACTION BETWEEN TUMOR-ASSOCIATED PLATELETS AND GLIOMA STEM CELLS IN GLIOBLASTOMA MULTIFORME (2019) (0)
CTNI-48. TRIAL UPDATE -RESULTS OF A PHASE I WINDOW OF OPPORTUNITY TRIAL EVALUATING A FIRST-IN-CLASS CD29 INHIBITOR, OS2966, IN RECURRENT HIGH-GRADE GLIOMA (2022) (0)
The future of clinical research beyond phase III trials. (2009) (0)
NTRK3 gene fusion in an adult ganglioglioma: illustrative case (2022) (0)
An Evaluation of Prognostic Factors of Elderly Patients With Low Grade Glioma (2017) (0)
Clinical Outcomes of Breast Brain Metastases by Subtype following LINAC Based Stereotactic Radiation (2020) (0)
Abstract A085: Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment (2018) (0)
Surgical and Anatomic Factors Predict Development of Leptomeningeal Disease in Patients with Melanoma Brain Metastases. (2022) (0)
RADI-25. REPEAT STEREOTACTIC RADIOSURGERY FOR RECURRENT BRAIN METASTASES (2019) (0)
Related articles (2012) (0)
25 Durable complete responses observed in patients with recurrent high grade glioma treated with Toca 511 & Toca FC (2018) (0)
Reply to P. Farace et al (2011) (0)
CTNI-41. INITIAL RESULTS OF A PHASE I WINDOW OF OPPORTUNITY TRIAL EVALUATING A FIRST-IN-CLASS CD29 INHIBITOR, OS2966, IN RECURRENT HIGH-GRADE GLIOMA (2021) (0)
Neurosurgical involvement in clinical trials for CNS tumors (2021) (0)
Targeting myeloid derived suppressor cells: Phase 0/1 trial of low dose capecitabine + bevacizumab in patients with recurrent glioblastoma. (2017) (0)
Prognostic Factors for Adult Low Grade Glioma Patients 40 Years of Age and Younger (2015) (0)
NCMP-03. ANATOMIC AND SURGICAL FACTORS PREDICT DEVELOPMENT OF LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC MELANOMA (2021) (0)
GENE-26. HOST GENETIC VARIATIONS IN MACROPHAGE MIGRATION INHIBITOR FACTOR CONFER WORSE PROGNOSIS IN GLIOBLASTOMA (2019) (0)
215 Extent of Resection in Glioblastoma: Prognostic Validation of a New Classification from the RANO Resect Group (2023) (0)
Disparities in Treatment of Low Grade Glioma by Race and Socioeconomic Status (2017) (0)
ATIM-25. IMMUNOLOGICAL ACTIVATION IN RESPONDING PATIENTS WITH RECURRENT HGG AFTER TREATMENT WITH TOCA 511 & TOCA FC: RESULTS FROM A PHASE 1 TRIAL (2017) (0)
Objective response rate (ORR) targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival. (2023) (0)
895 Desferoxamine Protects T Cells from Glioblastoma Multiforme-mediated Apoptosis and Improves Cytolytic Activity of T Cells in Killing of Tumor Targets. (2005) (0)
Targeting the IL4 Receptor with MDNA55 in Patients with Recurrent Glioblastoma: Results of a Phase 2b Trial. (2023) (0)
NIMG-77. IMPACT OF POST-SURGICAL ENHANCING TUMOR VOLUME AND T2/FLAIR VOLUME ON THE SURVIVAL IMPACT OF BEVACIZUMAB IN NRG ONCOLOGY/RTOG 0825 (2017) (0)
Health Care Expenditures Associated With the Management of Multiple Brain Metastases (2016) (0)
NCMP-21. IMMUNE-RELATED ACUTE MOTOR AXONAL NEUROPATHY: A SMALL CASE SERIES AND REVIEW OF THE LITERATURE (2021) (0)
SURG-10. The evolving role of neurosurgery for central nervous system metastases in the era of personalized medicine (2021) (0)
IMAGE-GUIDED TREATMENT OF METASTATIC BRAIN TUMORS (2005) (0)
Erratum: The importance of the conformality, heterogeneity, and gradient indices in evaluating gamma knife radiosurgery treatment plans for intracranial meningiomas (International Journal of Radiation Oncology Biology Physics (2012) 83:5 (1406-1413)) (2013) (0)
Hypothalamic Transplants (2014) (0)
TMIC-51. DEXAMETHASONE DRIVES MYELOID-DERIVED SUPPRESSOR CELL ACCUMULATION IN GLIOBLASTOMA IN A SEX-SPECIFIC MANNER (2018) (0)
STMC-15. INNATE IMMUNE SIGNALING VIA TLR4 SUPPRESSES SELF-RENEWAL IN GLIOBLASTOMA (2016) (0)
CTNI-51. NEUROCOGNITIVE FUNCTION (NCF) OUTCOMES OF RTOG FOUNDATION 3508: A PHASE 3 TRIAL OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH EGFR-AMPLIFIED NEWLY DIAGNOSED GBM (2020) (0)
LMD-19. Anatomic and Surgical Factors Predict Development of Leptomeningeal Disease in Patients with Metastatic Melanoma (2021) (0)
RTID-01. ONC108: A RANDOMIZED PHASE 3 STUDY OF ONC201 IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA (2022) (0)
Related articles (2013) (0)
Diagnosis and treatment of atypical and anaplastic meningiomas: A review. Comments (2005) (0)
1-3 Synchronous brain metastases in newly diagnosed non-small cell lung cancer ( NSCLC ) : validation of the disease specific GPA (2017) (0)
Apoptosis in glial brain tumors (2000) (0)
DDEL-08OVERALL SAFETY AND EFFICACY IN SUBJECTS WITH RECURRENT HGG TREATED ACROSS 2 TOCAGEN STUDIES - PROGNOSTIC FACTORS ASSOCIATED WITH SURVIVAL (2015) (0)
Optimizing Intracranial Disease Control for Breast Cancer Patients with HER2 Positive Brain Metastasis: Combining SRS and CNS-Penetrating HER2 Blockade Therapy (2017) (0)
NI-72CORRELATION OF VOLUMETRICAL ANALYSES DERIVED FROM 18FET-PET AND MRI WITH OUTCOME IN GLIOBLASTOMA PATIENTS (2014) (0)
CMET-17. RENAL CELL CARCINOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIATION THERAPY AND NIVOLUMAB DOES NOT ALTER LESIONAL OR CLINICAL OUTCOMES (2019) (0)
SCDT-06. QUANTIFIABLE LEVELS OF THE TRANSGENE, CYTOSINE DEAMINASE, IN TUMOR SAMPLES FOLLOWING INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (2017) (0)
PC3 - 151 Toca 5: A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined with Toca FC versus Standard of Care in Patients Undergoing Planned Resection for Recurrent Glioblastoma (GBM) or Anaplastic Astrocytoma (AA) (NCT02414165) (2016) (0)
AT-01PHASE I TRIAL OF DOSE ESCALATED RADIOSURGERY PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT/PROGRESSIVE GLIOBLASTOMA. (2014) (0)
ATIM-16. MRI-GUIDED CONVECTIVE DELIVERY OF MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA (2017) (0)
Personalized Radiosurgery for Brain Metastasis: Moving beyond Tumor Size in the Modern Stereotactic Radiosurgery Era (2017) (0)
(OA13) Stereotactic Radiosurgery and Concurrent Targeted Therapy: Improving the Response Rate for Breast Cancer Brain Metastasis (2018) (0)
MDNA55, a Locally Administered IL4 Guided Toxin for Targeted Treatment of Recurrent Glioblastoma Shows Long Term Survival Benefit. (2020) (0)
PRECLINICAL EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY (2010) (0)
Editorial. Considering the role of surgery for low-grade glioma in the molecular genetic era. (2020) (0)
NCMP-27. THE USE OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) DURING SEVERE NEUROTOXICITY AMONG THE RECIPIENTS OF CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) THERAPY (2020) (0)
SURG-20. FIRST IN-HUMAN STUDY OF A NOVEL DEVICE FOR CONVECTION ENHANCED DELIVERY OF TOPOTECAN AND GADOLINIUM FOR RECURRENT GBM: INTERIM RESULTS (2016) (0)
Metastatic Brain Tumors (2015) (0)
DDIS-27. COMBINED INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND POLY (ADP-RIBOSE) POLYMERASE (PARP) IMPAIRS GLIOBLASTOMA CELL GROWTH (2018) (0)
Abstract CT060: ACTION: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma (2023) (0)
Caspase-9 transduction overrides the resistance mechanism against p53-mediated apoptosis in U87MG glioma cells. (2002) (0)
Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases (2021) (0)
RADT-11. CLINICAL OUTCOMES IN THE MANAGEMENT OF MELANOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIOSURGERY AND ANTI-PD-1+CTLA-4 (2022) (0)
Abstracts IMMUNOTHERAPY / BIOLOGICAL THERAPIES IT-001. FEASIBILITY OF LYMPHOCYTE HARVESTING AND REINFUSION IN PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS (2013) (0)
CMET-11. IMPACT OF TUMOR SIZE AND MOLECULAR PROFILE ON LOCAL CONTROL IN PATIENTS WITH BREAST CANCER BRAIN METASTASES: UNDERSTANDING TUMOR BIOLOGY AND RADIOSURGERY DOSING (2017) (0)
4012 POSTER Stereotactic Radiosurgery of Brain Metastases in Elderly Patients: the Cleveland Clinic Experience (2011) (0)
OS04.2 First in human study of the Cleveland Multiport Catheter and convection enhanced delivery of topotecan and gadolinium for recurrent GBM: Updated results (2017) (0)
IMMU-17. LEVERAGING CORE EPIGENETIC PROGRAMMING OF IMMUNOSUPPRESSIVE MYELOID CELLS FOR THERAPEUTIC TARGETING OF GLIOBLASTOMA (2022) (0)
Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery (SRS) in patients with 1-3 newly diagnosed brain metastases. (2012) (0)
IMMU-28. TARGETING IMMUNOSUPPRESSIVE MYELOID DERIVED SUPPRESSOR CELLS VIA MIF/CD74 SIGNALING AXIS TO ATTENUATE GBM GROWTH (2019) (0)
The MIF SNP rs755622 is a germline determinant of tumor immune activation in Glioblastoma (2022) (0)
Book Review: Neuro-Oncology: The Essentials, Third Edition. (2015) (0)
CTIM-01. TITLE: PHASE 1B STUDY OF AVELUMAB AND WHOLE BRAIN RADIOTHERAPY (WBRT) IN PATIENTS WITH LEPTOMENINGEAL DISEASE (LMD): PRELIMINARY RESULTS (2022) (0)
How far have we really come? Trends in survival and mortality for gliomas between 1973 to 2014 from SEER. (2018) (0)
Adult low-grade gliomas: The Cleveland Clinic experience. (2012) (0)
LAB-IMMUNOLOGY RESEARCH (2012) (0)
BMET-17. THE PROGNOSTIC ROLE OF TUMOR VOLUME IN THE OUTCOME OF PATIENTS WITH SINGLE BRAIN METASTASIS AFTER STEREOTACTIC RADIOSURGERY (2016) (0)
ATIM-02. DURABLE RESPONSES OBSERVED IN IDH1 WILDTYPE AND MUTANT RECURRENT HIGH GRADE GLIOMA (rHGG) WITH TOCA 511 & TOCA FC TREATMENT. (2017) (0)
Glioblastoma, Part I: Surgical Management and Adjuncts (2021) (0)
Anaplastic oligodendroglial tumors: The Cleveland Clinic experience. (2012) (0)
IMCT-05COMBINABILITY OF TOCA FC AND TOCA 511 WITH CHEMOTHERAPY AND TARGETED AGENTS (2015) (0)
Avastin and Malignant Gliomas (2010) (0)
Newly Diagnosed Non-Small Cell Lung Cancer (NSCLC) With 1-3 Brain Metastases: Validation of the Disease Specific GPA (2015) (0)
Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone. (2022) (0)
Global immune fingerprinting in glioblastoma reveals immune-suppression signatures associated with prognosis (2018) (0)
ACTR-09. TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE + BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA (2016) (0)
Malignant Transformation of Adult Low Grade Glioma: Risk Factors and Outcomes in the Molecular Era (2019) (0)
Capecitabine and stereotactic radiation in the management of breast cancer brain metastases (2021) (0)
NIMG-42. DURABLE OVERALL RESPONSE RATE (ORR) TARGETS FOR RECURRENT GLIOBLASTOMA (RGBM) CLINICAL TRIALS BASED ON THE HISTORIC ASSOCIATION BETWEEN ORR AND MEDIAN OVERALL SURVIVAL (MOS) (2022) (0)
CADD-13. COMBINED INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND POLY (ADP-RIBOSE) POLYMERASE (PARP) IMPAIRS GLIOBLASTOMA CELL GROWTH (2018) (0)
Erlotinib in patients with recurrent or progressive glioblastoma multiforme (2006) (0)
Local Therapies (2019) (0)
Treatment of recurrent hgg patients with the retroviral replicating vector Toca 511 and Toca FC gives durable responses and survival lasting 3 years or longer: Immune mechanisms and molecular analyses of tumors (2018) (0)
ACTR-06. THE TOCA 7 STUDY: PHASE 1B STUDY OF TOCA 511, A LIVE GAMMA RETROVIRUS, AND TOCA FC, AN EXTENDED-RELEASE FORMULATION OF 5-FLUOROCYTOSINE COMBINED WITH STANDARD OF CARE IN NEWLY DIAGNOSED HIGH GRADE GLIOMA (NCT02598011) (2016) (0)
Does the sequence of stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT) affect treatment related morbidity in melanoma patients with brain metastasis? (2004) (0)
Use of virtual magnetic resonance imaging to compensate for brain shift during image-guided surgery: illustrative case (2022) (0)
CMET-06. AN ANALYSIS OF RESPONSE ENDPOINTS FOR BRAIN METASTASIS PATIENTS TREATED WITH STEREOTACTIC RADIOSURGERY AND PD(L)-1 INHIBITORS (2019) (0)
IMMU-70. GLOBAL IMMUNE FINGERPRINTING IN GLIOBLASTOMA REVEALS IMMUNE-SUPPRESSION SIGNATURES ASSOCIATED WITH PROGNOSIS (2018) (0)
SURG-26. READMISSION FOLLOWING RESECTION FOR PATIENTS WITH BRAIN METASTASES IN THE UNITED STATES (2019) (0)
Abstract OT2-09-01: Phase I/II study of stereotactic radiation and abemaciclib in the management of hormone receptor positive HER2 negative breast cancer brain metastases (2022) (0)
Pituitary Metastasis: The Moffitt Cancer Center Experience (2021) (0)
CTIM-28. MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, FOR RECURRENT GBM DELIVERED BY CONVECTION ENHANCED DELIVERY (CED) (2021) (0)
Introduction. Update on neuro-oncology (2022) (0)
Recursive Partitioning Analysis Identifies Prognostic Groups for Glioblastoma Patients Aged 70 Years or Older (P07.109) (2012) (0)
Adjuvant radiosurgery for a resected brain metastasis: A case report and literature review (2015) (0)
Abstract PS14-19: Characteristics of breast cancer brain metastases presentation by subtype and validation of the modified breast graded prognostic assessment (2021) (0)
IMMU-08. MODELING UPFRONT GLIOBLASTOMA SURGICAL RESECTION AND STEROID USE REVEALS IMMUNOSUPPRESSIVE CHANGES AND SUGGESTS THAT PERIPHERAL LYMPHOCYTE COUNTS ARE ASSOCIATED WITH TUMOR VOLUME AND PROGNOSIS (2020) (0)
Determining the Optimal Management of Patients With Limited-Brain Metastases: A Cost Analysis Approach (2015) (0)
Outcomes of Patients with Acoustic Neuromas Treated with Gamma Knife Radiosurgery (2008) (0)
IMMU-10. GENOMIC DIFFERENCES UNDERLIE MYELOID-DERIVED SUPPRESSOR CELL SEXUAL DIMORPHISM IN GLIOBLASTOMA (2020) (0)
Surgical Management of Glioblastoma: More Than Just Diagnosis and Decompression. (2021) (0)
Impact of 1p Status and Radiation Therapy Timing on Long-term Outcomes for Adults With Grade 2 Glioma Treated at a Single Institution (2013) (0)
Myeloid-derived suppressor cell subset heterogeneity drives glioblastoma progression in a sex-dependent manner (2020) (0)
Reply to A.A. Brandes et al (2011) (0)
147 Pathological Correlation of Cellular Imaging Using Apparent Diffusion Coefficient Quantification in Patients With Brain Metastases Following Gamma Knife Radiosurgery (2018) (0)
Risk Factors for Progression of Low Grade Glioma Following Gross Total Resection and Observation in the Molecular Era (2018) (0)
Capecitabine and stereotactic radiation in the management of breast cancer brain metastases (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael A. Vogelbaum?

Michael A. Vogelbaum is affiliated with the following schools:

University of Minnesota
University of South Florida
Case Western Reserve University
University of Virginia
University of Utah

Michael A. Vogelbaum's Academic­Influence.com Rankings

Michael A. Vogelbaum's Degrees

Why Is Michael A. Vogelbaum Influential?

Michael A. Vogelbaum's Published Works

Published Works

What Schools Are Affiliated With Michael A. Vogelbaum?

Michael A. Vogelbaum's AcademicInfluence.com Rankings